Frontlight ResearchEarly access
Taking people in United StatesNo phase
A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Carmel, Charlotte, Cincinnati, Houston, Madison, Manhasset, Milwaukee, Nashville, Philadelphia, Pittsburgh, Providence, Sacramento, Salt Lake City, and San Francisco, United StatesSee the 14 sites
- Trial code
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- 9 Feb 2026
- Expected to end
- 23 Nov 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Blood sample collection
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Presenting to the Emergency Department with a biomechanically plausible mechanism of non-penetrating traumatic brain injury (TBI; direct impact: blow to the head, head against object, object against head; acceleration/deceleration)
- Acute brain CT completed for standard of care; Further Inclusion Criteria (specific for CLIN12.2):
- Admitted to the hospital with radiographic evidence of acute TBI
- Admitted to the intensive care unit at risk for decline related to TBI
Who cannot take part
- Prior neurosurgical intervention within the last 6 months
- Received chemotherapy or radiation currently or within the last year
- Currently receiving any interventional treatments as a part of an investigational study/trial (drug, device, behavioral, treatment) at the time of enrollment and/or during the course of this study
- Major debilitating neurological disease (such as, but not limited to: stroke, CVA, mild cognitive impairment, Alzheimer's disease, Amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, Frontotemporal dementia, tumor, epilepsy, unmanaged seizure disorder), impairing baseline awareness, cognition, or validity of outcomes assessments
- Major debilitating baseline mental health disorders (such as but not limited to schizophrenia or bipolar disorder) that would interfere with follow-up and the validity of outcome assessments
- Significant pre-existing conditions that would interfere with follow-up and outcome assessment (such as, but not limited to: chronic kidney disease, chronic cardiovascular comorbidities, alcohol or substance use disorder)
- History of melanoma
- Primary diagnosis of ischemic or hemorrhagic stroke
- Patients on psychiatric hold (e.g., 5150, 5250)
- Any condition that, in the opinion of the investigator, could interfere in the proper execution of the study procedures and/or in their future permanence in the study
- Any spinal Cord Injury (American Spinal Injury Association [ASIA] score of A-D)
- Current incarceration or in custody
- Known inability to undergo an MRI
- Low likelihood of follow-up (e.g. participant or family indicating low interest, residence in another state or country, homelessness or lack of reliable contacts)
Where in United States
- Goodman Campbell Brain and Spine/AscensionCarmel, United StatesContact: Marian MartinezNot yet recruiting
- Atrium Health - Carolina Medical CenterCharlotte, United StatesContact: Marian MartinezTaking people
- University of CincinnatiCincinnati, United StatesContact: Marian MartinezTaking people
- Baylor College of MedicineHouston, United StatesContact: Marian MartinezNot yet recruiting
- University of WisconsinMadison, United StatesContact: Marian MartinezNo longer taking part
- Northwell Health - Department Of NeurosurgeryManhasset, United StatesContact: Marian MartinezNot yet recruiting
- Medical College of WisconsinMilwaukee, United StatesContact: Marian MartinezNot yet recruiting
- Vanderbilt University Medical CenterNashville, United StatesContact: Marian MartinezNot yet recruiting
- University of Pennsylvania Medical CenterPhiladelphia, United StatesContact: Marian MartinezTaking people
- University of Pittsburgh Medical CenterPittsburgh, United StatesContact: Marian MartinezTaking people
- Brown UniversityProvidence, United StatesContact: Marian MartinezNot yet recruiting
- University Of California Davis, Neurological SurgerySacramento, United StatesContact: Marian MartinezTaking people
- University of UtahSalt Lake City, United StatesContact: Marian MartinezNot yet recruiting
- University of California San FranciscoSan Francisco, United StatesContact: Marian MartinezTaking people
About the trial
What the trial wants to find out
The study is intended to cover two purposes: first, to develop a blood-based biomarker test for aiding the diagnosis of traumatic brain injury (TBI) in adult participants and for prognosis of outcome of TBI (CLIN12.1); and second, for monitoring the development of secondary events in adult participants diagnosed with TBI (CLIN12.2).
The 2 groups in the trial
- Cohort 1: Participants with Suspected TBI
Treatment: Blood sample collection
- Cohort 2: Hospitalized Participants with TBI
Treatment: Blood sample collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter Prospective Study to Develop a Blood-based Biomarker Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adult Subjects (CLIN12.1) and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury (CLIN12.2)
- Record updated
- 13 November 2026